Amphastar Pharmaceuticals Q3 net income more than doubles to $37.76 million

• Amphastar Pharmaceuticals’ third-quarter 2026 GAAP net income more than doubled year over year to $37.76 million.
• Net revenues rose 8% to $207.61 million, while gross margin fell to 48% from 51.4% a year earlier.
• Margin pressure stemmed from lower selling prices and increased manufacturing expenses, including IMS remediation costs.
• General and administrative expenses dropped 57% to $16.84 million, primarily due to a litigation provision recorded a year earlier.
• The board authorized a $50 million increase in the share buyback program, primarily to offset equity-compensation dilution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA88634) on November 05, 2026, and is solely responsible for the information contained therein.